Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akero Therapeutics, Inc. (AKRO)
|
Add to portfolio |
|
|
|
| Price: |
$20.74
| | Metrics |
| OS: |
55.6
|
M
| |
|
|
| Market cap: |
$1.15
|
B
| |
|
|
|
Net cash:
|
$634
|
M
| |
$11.41
|
per share
|
|
EV:
|
$519
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Research and development | 85.3 | 81.8 | 64.9 | 37.0 | 11.9 |
| General and administrative | 29.9 | 19.1 | 15.2 | 8.6 | 1.9 |
| EBIT | -115.2 | -100.9 | -80.2 | -45.7 | -13.8 |
| Pre-tax income | -112.0 | -100.8 | -79.2 | -43.7 | -81.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -112.0 | -100.8 | -79.2 | -43.8 | -82.2 |
| |
| Diluted EPS | ($2.87) | ($2.89) | ($2.52) | ($2.90) | ($795.28) |
| Shares outstanding (diluted) | 39.0 | 34.8 | 31.5 | 15.1 | 0.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|